Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Home Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations

/ Publications

Share the Post

About the Author

Related Posts

Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
Read More
Loretta Itri, MD
Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors
Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of nab-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting
nab-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in PTEN null bladder cancer (UMUC3) and TSC2 null liver cancer (SNU398) xenografts
Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Phase 2 Study of nab-Sirolimus in Patients with Well-differentiated and Advanced or Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract, Lung, or Pancreas

Comments

Comments are closed.